Abstract
Retinoblastoma (RB) is the most common intraocular tumor among children. Leucine-rich pentatricopeptide repeat (PPR)-motif-containing protein (LRPPRC), a suppressor gene of autophagy, has been proven to play a regulatory role in tumor progression. However, little is known about functional roles and mechanisms of LRPPRC in RB progression. First, we performed a detailed analysis for RB and normal control. The expression of LRPPRC in the RB tissues was significantly higher than that in normal tissues. Moreover, LRPPRC suppression could repress tumor cell migration, invasion, glycolysis, and reactive oxygen species (ROS)/hypoxia-inducible factor-1α (HIF1-α) pathway activation by mediating autophagy. Furthermore, overexpression of HIF1-α partially reversed the above changes induced by LRPPRC knockdown. The regulation of LRPPRC on tumor metastasis and glycolysis was also validated by a xenograft tumor assay. In summary, LRPPRC could regulate metastasis and glycolysis of RB by mediating autophagy suppression and further activating the ROS/HIF1-α pathway, and LRPPRC could be a promising prognostic biomarker for RB.
Full Text
Topics from this Paper
Full Text PDF PubMed Scopus
PubMed Scopus
Levels Of Light Chain 3
Expression Levels Of Light Chain 3
Google Scholar
+ Show 5 more
Create a personalized feed of these topics
Get StartedTalk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Similar Papers
Journal of Investigative Dermatology
Mar 1, 2016
Journal of Biological Chemistry
Aug 1, 2004
Journal of Biological Chemistry
Mar 1, 2011
iScience
Nov 1, 2020
Experimental Hematology
Sep 1, 2016
Journal of Biological Chemistry
Nov 1, 2010
Journal of Biological Chemistry
Aug 1, 2008
Journal of Biological Chemistry
Jan 1, 2011
Gastroenterology
Mar 1, 2015
Journal of Biological Chemistry
Jun 1, 2005
Journal of Biological Chemistry
May 1, 2001
Journal of Biological Chemistry
Apr 1, 2011
Journal of Biological Chemistry
Apr 1, 2003
Trends in Endocrinology & Metabolism
Aug 1, 2020
Journal of Biological Chemistry
Feb 1, 2003
Molecular Therapy - Oncolytics
Molecular Therapy - Oncolytics
Dec 1, 2023
Molecular Therapy - Oncolytics
Dec 1, 2023
Molecular Therapy - Oncolytics
Dec 1, 2023
Molecular Therapy - Oncolytics
Dec 1, 2023
Molecular Therapy - Oncolytics
Dec 1, 2023
Molecular Therapy - Oncolytics
Dec 1, 2023
Molecular Therapy - Oncolytics
Dec 1, 2023
Molecular Therapy - Oncolytics
Nov 1, 2023
Molecular Therapy - Oncolytics
Nov 1, 2023
Molecular Therapy - Oncolytics
Nov 1, 2023